Editas Medicine Names David Scadden, M.D., to Board of Directors
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed David T. Scadden, M.D., to its Board of Directors, effective immediately. Dr. Scadden is a hematologist/oncologist and an expert on the medical applications of stem cell biology with a particular emphasis on its use in the settings of cancer and AIDS. He is the Gerald and Darlene Jordan Professor of Medicine and is Professor of Stem Cell and Regenerative Biology at Harvard University. He co-founded and co-directs the Harvard Stem Cell Institute and is the Director of the Center for Regenerative Medicine at Massachusetts General Hospital. He has published more than 300 scientific papers and book chapters, and his laboratory has made fundamental contributions in understanding the regulation of stem cell function. Dr. Scadden is the recipient of numerous honors, including membership in the National Academy of Medicine, the
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire
- Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer [Yahoo! Finance]Yahoo! Finance
- Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
EDIT
Earnings
- 2/28/24 - Beat
EDIT
Sec Filings
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- 4/10/24 - Form SC
- EDIT's page on the SEC website